Navidea Says Lymphoseek Results Statistically Significant, Results Unveiled at SNMMI

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB ), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from two separate studies that compared the performance of Lymphoseek^® (technetium Tc 99m tilmanocept) Injection, a novel receptor-targeted small-molecule radiopharmaceutical recently approved by the U.S. Food and Drug Administration, with that of radiolabeled sulfur colloid in breast